Genmab nears deal to acquire Dutch cancer drugmaker Merus, Bloomberg News reports
28/09/2025 23:25
Sept 28 (Reuters) - Denmark’s Genmab GMAB.CO is in advanced talks to acquire Merus NV 2GH.F, a Nasdaq-listed Dutch biotech firm developing a head-and-neck cancer drug, Bloomberg News reported on Sunday. (Reporting by Rajveer Singh Pardesi in Bengaluru; Editing by Leslie Adler) ((RajveerSingh.Pardesi@thomsonreuters.com;))
Recent news on Genmab A/S
See all newsBrief: Genmab Says Orbis Investment Management Holds 4.99% Of Genmab Voting Rights As Of June 12
Brief: Genmab Announces Epcoritamab Monotherapy And Epcoritamab-Based Combination Regimens Demonstrate High Response Rates In Elderly Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma
Brief: Genmab Presents Epcore Fl-1 Data Showing Consistent Efficacy, Safety For Epcoritamab Combination
Brief: Genmab Says Orbis Investment Management Limited Holds 5.08% Of Genmab A/S As Of May 8, 2026
Genmab falls after 'uneventful' Q1, profit miss